Iconic Therapeutics, based in San Francisco, California, is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer.
The Company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in age-related macular degeneration (“AMD”). By targeting inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. Iconic has completed a Phase 1 clinical trial in wet AMD and has completed enrolment in EMERGE, a Phase 2a study in newly diagnosed AMD patients. The Company is investigating the ICON family of proteins in cancer and has initiated a research programme in solid tumours.
1. William L. Greene, MD (CEO and Director)
Dr. Greene joined Iconic Therapeutics as the Chief Executive Officer and a Director in April 2014. He has 20 years of experience as an operating executive, clinician, investor and entrepreneur. Prior to Iconic, Dr. Greene was at MPM Capital LLC, where he served as Managing Director and a member of the firm’s Investment Committee leading investments (including in Iconic) and serving on Boards of Directors of emerging biopharmaceutical and medical device companies.
Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, Inc., with responsibility for clinical strategy, trial design and execution and regulatory interactions in several therapeutic areas at all stages of development. While at Genentech, Dr. Greene led the early clinical development of Lucentis. Prior to Genentech, Dr. Greene was at Yale Medical School as a Resident in Internal Medicine and Diagnostic Radiology. Dr. Greene received a B.A. degree from Wesleyan University and an M.D. degree from UCSF and is a member of the American College of Physicians.
2. Kirk Dornbush (President and Co-Founder)
Mr. Dornbush co-founded Iconic and served as its Chief Executive Officer from 2007 until 2014. Under his leadership, Iconic advanced ICON-1, the Company’s lead asset, through non-clinical development and completed a successful Phase 1 study in wet AMD. Prior to Iconic’s inception, Mr Dornbush was President of Diem Investments, a private investment advisory firm. He continues to serve as manager of Diem Bioventures, LLC, an investor in Iconic. Mr. Dornbush received his B.A. in English from The Colorado College and his JD from Boston University School of Law.
3. Gabriela Burian, MD, MPH (Chief Medical Officer)
Dr. Burian brings to Iconic more than 15 years of clinical research and development experience focused on retinal disease, with extensive practice in designing, planning, and executing global clinical programmes. Prior to Iconic, she was with Novartis and held various leadership and management positions including being the Global Program Medical Director. Dr. Burian was also responsible for clinical development strategies across multiple retinal indications, which included age-related macular degeneration, diabetic macular oedema (“DME”), retinal vein occlusion (“RVO”) and pathologic myopia (“PM”) and successfully led the global (ex-US) regulatory interactions and approvals of Lucentis® for DME, RVO and PM in more than 100 countries.
Dr. Burian received her M.D. degree from Victor Babes University of Medicine and Pharmacy in Romania, and her Master’s in Public Health in Epidemiology from Rollins School of Public Health at Emory University.